JP2000516585A - 血管新生阻害物質による雌生殖系の調節方法 - Google Patents

血管新生阻害物質による雌生殖系の調節方法

Info

Publication number
JP2000516585A
JP2000516585A JP10508217A JP50821798A JP2000516585A JP 2000516585 A JP2000516585 A JP 2000516585A JP 10508217 A JP10508217 A JP 10508217A JP 50821798 A JP50821798 A JP 50821798A JP 2000516585 A JP2000516585 A JP 2000516585A
Authority
JP
Japan
Prior art keywords
angiogenesis
agm
mice
inhibiting
female
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10508217A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000516585A5 (enExample
Inventor
ディー’アマート，ロバート，ジェイ．
クラウバー，ナンシー
Original Assignee
ザ チルドレンズ メディカル センター コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ チルドレンズ メディカル センター コーポレイション filed Critical ザ チルドレンズ メディカル センター コーポレイション
Publication of JP2000516585A publication Critical patent/JP2000516585A/ja
Publication of JP2000516585A5 publication Critical patent/JP2000516585A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP10508217A 1996-08-02 1997-08-01 血管新生阻害物質による雌生殖系の調節方法 Pending JP2000516585A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2338596P 1996-08-02 1996-08-02
US60/023,385 1996-08-02
PCT/US1997/013882 WO1998005323A2 (en) 1996-08-02 1997-08-01 Method of regulating the female reproductive system through angiogenesis inhibitors

Publications (2)

Publication Number Publication Date
JP2000516585A true JP2000516585A (ja) 2000-12-12
JP2000516585A5 JP2000516585A5 (enExample) 2005-04-07

Family

ID=21814780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10508217A Pending JP2000516585A (ja) 1996-08-02 1997-08-01 血管新生阻害物質による雌生殖系の調節方法

Country Status (6)

Country Link
US (3) US6017949A (enExample)
EP (1) EP0957910A2 (enExample)
JP (1) JP2000516585A (enExample)
AU (2) AU3968597A (enExample)
CA (1) CA2262535A1 (enExample)
WO (2) WO1998005293A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526609A (ja) * 2008-07-03 2011-10-13 バイエル オイ 避妊のための子宮内用送達システム

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ304906A (en) * 1995-03-27 1999-06-29 Sanofi Sa Use of fumagillol or a fumagillol ester and an optionally saturated alkylcarboxylic or alkyldicarboxylic acid to fight intestinal infections
AU4808997A (en) * 1996-09-30 1998-04-24 Brigham And Women's Hospital Methods and compounds for treatment of abnormal uterine bleeding
DE69824750T2 (de) * 1997-10-31 2005-07-07 Children's Medical Center Corp., Boston Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
JP4841724B2 (ja) * 1998-10-09 2011-12-21 ベジェニクス ピーティーワイ リミテッド 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）
US7141607B1 (en) * 2000-03-10 2006-11-28 Insite Vision Incorporated Methods and compositions for treating and inhibiting retinal neovascularization
CA2497497A1 (en) * 2002-09-04 2004-03-18 Proteinexpress Co., Ltd. Regulators for implantation
US20040266688A1 (en) * 2003-05-14 2004-12-30 Nayak Nihar R Methods for modulating endometrium
US20070213126A1 (en) * 2003-07-14 2007-09-13 Fusion Sport International Pty Ltd Sports Training And Testing Methods, Appartaus And System
JP2007525972A (ja) * 2003-08-29 2007-09-13 チルドレンズ メディカル センター コーポレーション エンドスタチンのｎ末端からの抗血管新生性ペプチド
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
EP2285989B1 (en) 2008-05-15 2016-11-16 The University of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
EP2317845A4 (en) * 2008-07-18 2011-11-09 Zafgen Inc METHOD FOR TREATING AN OVERWEIGHT OR FATABLE PERSON
WO2010012002A1 (en) * 2008-07-25 2010-01-28 Saryna Medical Corporation Methods and systems for genetic analysis of fetal nucleated red blood cells
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2011044506A2 (en) 2009-10-09 2011-04-14 Zafgen Corporation Sulphone compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
BR112012016793A2 (pt) 2010-01-08 2018-07-31 Zafgen Corp compostos tipo fumagilol e métodos de fazer e usar os mesmos
RU2427325C1 (ru) * 2010-01-29 2011-08-27 Государственное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО АГМА Росздрава) Способ оценки эффективности лечения хронической плацентарной недостаточности в эксперименте
US8774488B2 (en) 2010-03-11 2014-07-08 Cellscape Corporation Method and device for identification of nucleated red blood cells from a maternal blood sample
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
CN103079567A (zh) 2010-04-17 2013-05-01 拜尔健康护理有限责任公司 用于疾病和病症的治疗和预防的氟取代的ω-羧基芳基二苯脲的合成代谢产物
JP2013531067A (ja) 2010-07-19 2013-08-01 バイエル ヘルスケア リミティド ライアビリティ カンパニー 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
JP2013543899A (ja) 2010-11-29 2013-12-09 ザフゲン，インコーポレイテッド ６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールの非連日投与を用いた肥満の治療
US9321740B2 (en) 2011-01-26 2016-04-26 Zafgen, Inc. Tetrazole compounds and methods of making and using same
AU2012225531B2 (en) 2011-03-08 2017-03-30 Zafgen, Inc Oxaspiro (2.5) octane derivatives and analogs
US9290472B2 (en) 2011-05-06 2016-03-22 Zafgen, Inc. Partially saturated tricyclic compounds and methods of making and using same
WO2012154679A1 (en) 2011-05-06 2012-11-15 Zafgen Corporation Tricyclic pyrazole sulfonamide compounds and methods of making and using same
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
AU2013209719A1 (en) 2012-01-18 2014-08-07 Zafgen, Inc. Tricyclic sulfone compounds and methods of making and using same
BR112014027808A2 (pt) 2012-05-07 2017-06-27 Zafgen Inc sal polimórfico do sal de oxalato de 6-o-(4-dimetilaminoetoxi) cinaroil fumagilol e métodos de produção e utilização do mesmo
EP2846792B1 (en) 2012-05-08 2018-08-15 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
CN104364251B (zh) 2012-05-09 2017-02-22 扎夫根股份有限公司 烟曲霉醇型化合物及其制备和使用方法
CN104918928A (zh) 2012-11-05 2015-09-16 扎夫根股份有限公司 三环化合物及其制备方法和用途
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
NZ707773A (en) 2012-11-05 2019-05-31 Zafgen Inc Methods of treating liver diseases
KR20150126924A (ko) 2013-03-14 2015-11-13 자프겐 인크. 신장 질환 및 기타 장애의 치료 방법
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1226816A (en) * 1982-12-20 1987-09-15 Moses J. Folkman Inhibition of angiogenesis
DE3344797A1 (de) * 1983-12-10 1985-06-20 Th. Kieserling & Albrecht Gmbh & Co, 5650 Solingen Transportvorrichtung fuer felgenrohlinge
US4599331A (en) * 1984-12-24 1986-07-08 Syntex (U.S.A.) Inc. Etianic acids as antiangiogenics
DE68915900T2 (de) * 1988-09-01 1994-11-24 Childrens Medical Center Angiogenese hemmendes Mittel.
US5086164A (en) * 1989-01-10 1992-02-04 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
CA2081205C (en) * 1990-06-11 2001-02-27 John W. Wilks Steroids which inhibit angiogenesis
FR2672801B1 (fr) * 1991-02-14 1995-03-03 Sanofi Sa Utilisation de derives de tetrahydrothienopyridine comme inhibiteurs de l'angiogenese.
GB9225475D0 (en) * 1992-12-05 1993-01-27 Imp Cancer Res Tech Compounds to combat angiogenesis
CA2157927C (en) * 1993-03-12 1999-03-30 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein produc ts
EP0658342B1 (en) * 1993-09-24 1999-03-17 Takeda Chemical Industries, Ltd. Antineoplastic pharmaceutical composition containing a fumagillol derivative and a platinum complex
GB9410534D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
GB9410533D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
EP0857210B1 (en) * 1995-10-23 2003-09-03 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526609A (ja) * 2008-07-03 2011-10-13 バイエル オイ 避妊のための子宮内用送達システム

Also Published As

Publication number Publication date
US6017949A (en) 2000-01-25
US6441027B1 (en) 2002-08-27
US20020156055A1 (en) 2002-10-24
AU3910797A (en) 1998-02-25
AU3968597A (en) 1998-02-25
CA2262535A1 (en) 1998-02-12
WO1998005293A2 (en) 1998-02-12
EP0957910A2 (en) 1999-11-24
WO1998005323A3 (en) 1998-05-07
WO1998005323A2 (en) 1998-02-12

Similar Documents

Publication Publication Date Title
US6441027B1 (en) Method of regulating the female reproductive system through angiogenesis inhibitors
WO1998005323A9 (en) Method of regulating the female reproductive system through angiogenesis inhibitors
Dabrosin et al. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis
Webster et al. The effect of hypoxia in development
Teel The effects of injecting anterior hypophysial fluid on the course of gestation in the rat
Oliva et al. Unopposed estrogens: current and future perspectives.
JP2001506638A (ja) 白内障の予防または制御方法
WO2023230619A1 (en) Prevention of estrus in sow and ruminants
US20230381198A1 (en) Prevention of estrus in sow and ruminants
Segal et al. Contraceptive Technology Current and Prospective Methods
Sadeq et al. Comparative analysis of oral and local intraovarian administration of metformin and nanoparticles (NPs11) in alleviating testosterone-induced polycystic ovary syndrome in rats
DOWNING et al. Rat myometrial activity in vivo: Effects of oestradiol-17β and progesterone in relation to the concentrations of cytoplasmic progesterone receptors
Nalbandov Mechanisms controlling ovulation of avian and mammalian follicles
Wang et al. Chicoric acid ameliorates rat salpingitis by inhibiting the Nrf2/Notch1 signaling pathway
Marston et al. The time and site of contraceptive action of an intra-uterine device in the mouse
Soloff Endocrine control of parturition
Liggins Fetal influences on myometrial contractility
PINCUS The physiology of ovarian hormones
Kendle et al. Investigations into the mechanism of the antifertility action of minimal doses of megestrol acetate in the rabbit
RU2755250C1 (ru) Препарат на основе стероидных эстрогенов для лечения эндометриоза
Clausen et al. Vascular reactivity of the preplacental vasculature in guinea pigs
Hadi et al. The effects of quercetin on the expression of collagen I, collagen III and elastin in vaginal: an experimental animal study
David et al. Effect of the intrauterine contraceptive device on the regeneration of rabbit endometrium
Oxenreider et al. Regression of corpora lutea in unilaterally pregnant guinea-pigs
CN113456630B (zh) 血管生长因子受体抑制剂的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040730

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080423

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080529

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080722